Review paper: Current strategies in the development of Anti-obesity drugs and their safety concerns

Veterinary Pathology

Volumn 46, Issue 1, 2009, Pages 10-24

  Elangbam, C S ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Antiobesity drugs; Pulmonary arterial hypertension; Safety issues; Valvulopathy

Indexed keywords

ANIMALIA;

ANTIOBESITY AGENT;

ANIMAL; DRUG DEVELOPMENT; GENETICS; HUMAN; HYPERTENSION; METABOLISM; METHODOLOGY; PATHOLOGY; PHYSIOLOGY; PULMONARY ARTERY; REVIEW; SIGNAL TRANSDUCTION; VALVULAR HEART DISEASE;

ANIMALS; ANTI-OBESITY AGENTS; DRUG DISCOVERY; HEART VALVE DISEASES; HUMANS; HYPERTENSION; PULMONARY ARTERY; SIGNAL TRANSDUCTION;

EID: 63249123940     PISSN: 03009858     EISSN: 15442217     Source Type: Journal    
DOI: 10.1354/vp.46-1-10     Document Type: Article

References (137)

1. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G, Begaud B: Appetite-suppressant drugs and the risk of pulmonary hypertension. N Engl J Med 335:609-616, 1996
2. Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM: Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 8:1-182, 2004
3. Ballinger A, Peikin SR.: Orlistat: Its current status as an anti-obesity drug. Eur J Pharmacol 440:109- 117, 2002
4. Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO: Overweight as an avoidable cause of cancer in Europe. Int J Cancer 91:421-430, 2001
5. Blanpain C, Le Poul E, Parma J, Knoop C, Detheux M, Parmentier M, Vassart G, Abramo- wicz MJ: Serotonin 5-HT(2B) receptor loss of function mutation in a patient with fenfluramine- associated primary pulmonary hypertension. Car- diovasc Res 60:518-528, 2003
6. Boyd TS, Fremming BA: Rimonabant: a selective CB1 antagonist. Ann Pharmacother 39:684-690, 2005
7. Bratter J, Gessner IH, Rowland NE: Effects of prenatal co-administration of phentermine and dexfenfluramine in rats. Eur J Pharmacol 369:R1- R3, 1999
8. Bray GA: Medical consequences of obesity. J Clin Endocrinol Metab 89:2583-2589, 2004
9. Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K: Bariatric surgery: a systematic review and meta-analysis. J Am Med Assoc 292:1724-1737, 2004
10. Carai MA, Colombo G, Gessa GL: Rimonabant: the first therapeutically relevant cannabinoid antagonist. Life Sci 77:2339-2350, 2005
11. Chan SY, Loscalzo J: Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol 44:14-30, 2008
12. Chaput JP, St-Pierre S, Tremblay A: Currently available drugs for the treatment of obesity: sibutra- mine and orlistat. Mini Rev Med Chem 7:3-10, 2007
13. Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV: Valvular heart disease associated with fenflur- amine-phentermine. N Engl J Med 337:581-588, 1997
14. Cooke D, Bloom S: The obesity pipeline: current strategies in the development of anti-obesity drugs. Nat Rev Drug Discov 5:919-931, 2006
15. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thone-Reineke C, Ortmann S, Tomassoni F, Cervino C, Nisoli E, Linthorst AC, Pasquali R, Lutz B, Stalla GK, Pagotto U: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423-431, 2003
16. Daniels J: Obesity: America's epidemic. Am J Nurs 106:40-49, 2006
17. De Petrocellis L, Cascio MG, Di Marzo D: The endocannabinoid system: a general view and latest additions. Br J Pharmacol 141:765-774, 2004
18. Despres JP, Golay A, Sjostrom L: Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353:2121-2134, 2005
19. Di Marzo D, Bifulco M, De Petrocellis L: The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3:771-784, 2004
20. Di Marzo D, Matias I: Endocannabinoid control of food intake and energy balance. Nat Neurosci 8:585-589, 2005
21. Droogmans S, Franken PR, Garbar C, Weytjens C, Cosyns B, Lahoutte T, Caveliers V, Pipeleers- Marichal M, Bossuyt A, Schoors D, Van Camp G: In vivo model of drug-induced valvular heart disease in rats: pergolide-induced valvular heart disease demonstrated with echocardiography and correlation with pathology. Eur Heart J 28:2156- 2162, 2007
22. Eddahibi S, Adnot S, Frisdal E, Levame M, Hamon M, Raffestin B: Dexfenfluramine-associat- ed changes in 5-hydroxytryptamine transporter expression and development of hypoxic pulmonary hypertension in rats. J Pharmacol Exp Ther 297:148-154, 2001
23. Eddahibi S, Raffestin B, Hamon M, Adnot S: Is the serotonin transporter involved in the pathogenesis of pulmonary hypertension? J Lab Clin Med 139:194-201, 2002
24. Eddahibi S, Raffestin B, Pham I, Launay JM, Aegerter P, Sitbon M, Adnot S: Treatment with 5- HT potentiates development of pulmonary hypertension in chronically hypoxic rats. Am J Physiol 272:H1173-H1181, 1997
25. Elangbam CS, Colman KA, Lightfoot RM, Tyler RD, Wall HG: Endocardial myxomatous change in Harlan Sprague Dawley rats (Hsd:S-D) and CD-I mice: its microscopic resemblance to drug-induced valvulopathy in humans. Toxicol Pathol 30:483- 491, 2002
26. Elangbam CS, Job LE, Zadrozny LM, Barton JC, Yoon LW, Gates LD, Slocum N: 5-Hydroxytryp- tamine (5HT)-induced valvulopathy: compositional valvular alterations are associated with 5HT2B receptor and 5HT transporter transcript changes in Sprague-Dawley rats. Exp Toxicol Pathol 60:253- 262, 2008
27. Elangbam CS, Lightfoot RL, Yoon LW, Creech DR, Geske RS, Crumbley CW, Gates L, Wall HG: 5-Hydroxytryptamine (5HT) receptors in the heart valves of Cynomolgus monkeys and Sprague-Dawley rats. J Histochem Cytochem 53:671-677, 2005
28. Elangbam CS, Wehe JG, Barton JC, Krull DL, Nyska A, Crabbs TA, Kissling G: Evaluation of glycosaminoglycans content and 5-hydroxytryptamine 2B receptor in rat heart valves with spontaneous mitral valvulopathy: a possible exacerbation by dl, amphetamine sulfate in Fischer rats. Exp Toxicol Pathol 58:89-99, 2006
29. Fanburg BL, Lee SL: A new role for an old molecule: serotonin as a mitogen. Am J Physiol 272:L795-L806, 1997
30. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS: Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 31:53-65, 2008
31. Finer N, James WP, Kopelman PG, Lean ME, Williams G: One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 24:306-313, 2000
32. Fishman AP: Aminorex to fen/phen: an epidemic foretold. Circulation 99:156-161, 1999
33. Fitzgerald LW, Burn TC, Brown BS, Patterson JP, Corjay MH, Valentine PA, Sun JH, Link JR, Abbaszade I, Hollis JM, Largent BL, Hartig PR, Hollis GF, Meunier PC, Robichaud AJ, Robertson DW: Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol Pharmacol 57:75-81, 2000
34. Flum DR, Salem I, Elrod JA, Dellinger EP, Cheadle A, Chan I: Early mortality among Medicare beneficiaries undergoing bariatric surgical procedures. J Am Med Assoc 294:1903-1908, 2005
35. Freund TF, Katona I, Piomelli D: Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83:1017-1066, 2003
36. Fristrom S, Airaksinen MM, Halmekoski J: Release of platelet 5-hydroxytryptamine by some anorexic and other sympathomimetics and their acetyl derivatives. Acta Pharmacol Toxicol (Co- penh) 41:218-224, 1977
37. Gary-Bobo M, Elachouri G, Scatton B, Le Fur G, Oury-Donat F, Bensaid M: The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 69:471178, 2006
38. Gomez R, Navarro M, Ferrer B, Trigo JM, Bilbao A, Del Arco I, Cippitelli A, Nava F, Piomelli D, Rodriguez de Fonseca F: A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 22:9612-9617, 2002
39. Greenway FL, Caruso MK: Safety of obesity drugs. Expert Opin Drug Saf 4:1083-1095, 2005
40. Guignabert C, Izikki M, Tu LI, Li Z, Zadigue P, Barlier-Mur AM, Hanoun N, Rodman D, Hamon M, Adnot S, Eddahibi S: Transgenic mice overex- pressing the 5-hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res 98:1323-1330, 2006
41. Gurtner HP: Aminorex and pulmonary hypertension. Cor Vasa 27:160-171, 1985
42. Gustafsson BI, Tommeras K, Nordrum I, Loenne- chen JP, Brunsvik A, Solligard E, Fossmark R, Bakke I, Syversen U, Waldum H: Long-term serotonin administration induces heart valve disease in rats. Circulation 111:1517-1522, 2005
43. Halford JCG: Obesity drugs in clinical development. Curr Opin Invest Drugs 7:312-318, 2006
44. Halpern A, Mancini MC: Treatment of obesity: an update on antiobesity medications. Obes Rev 4:25-42, 2002
45. Hart CM, Block ER: Lung serotonin metabolism. Clinics Chest Med 10:59-70, 1989
46. Haslam DW, James WPT: Obesity. Lancet 366:1197-1209, 2005
47. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR: Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 9:160-167, 2000
48. Heck AM, Yanovski JA, Calis KA: Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 20:270-279, 2000
49. Hermann H, Marsicano G, Lutz B: Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal sub- populations of the adult mouse forebrain. Neuro- science 109:451-460, 2002
50. Hershel J: Heart valve disorders and appetite- suppressant drugs. JAMA 283:1738-1740, 2000
51. Herve P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P, Poubeau P, Cerrina J, Duroux P, Drouet L: Increased plasma serotonin in primary pulmonary hypertension. Am J Med 99: 249-254, 1995
52. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, McCamish M: Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA 282:1568- 1575, 1999
53. Hofbauer KG, Nicholson JR: Pharmacotherapy of obesity. Exp Clin Endocrinol Diabetes 114:475- 484, 2006
54. Hollander P: Orlistat in the treatment of obesity. Primary Care 30:427-440, 2003
55. Horvath T: Endocannabinoids and the regulation of body fat: the smoke is clearing. J Clin Invest 112:323-326, 2003
56. Howlett AC, Breivogel CS, Childers SR, Dead- wyler SA, Hampson RE, Porrino LJ: Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 47:345-358, 2004
57. Humbert M, Deng Z, Simonneau G, Barst RJ, Sitbon O, Wolf M, Cuervo N, Moore KJ, Hodge SE, Knowles JA, Morse JH: BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 20:518- 523, 2002
58. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, Rabinovitch M: Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43:13S-24S, 2004
59. Ioannides-Demos LL, Proietto J, Tonkin AM, McNeil JJ: Safety of drug therapies used for weight loss and treatment of obesity. Drug Saf 29:277-302, 2006
60. Irigaray P, Newby JA, Lacomme S, Belpomme D: Overweight/obesity and cancer genesis: more than a biological link. Biomed Pharmacother 61:665-678, 2007
61. Jahnichen S, Horowski R, Pertz HH: Agonism at 5HT2B receptors is not a class effect of the ergolines. Eur J Pharmacol 513:225-228, 2005
62. James WP, Astrup A, Finer N, Hilsted J, Kopel- man P, Rossner S, Saris WH, Van Gaal LF: Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet 356:2119-2125, 2000
63. Jeffery TK, Bryan-Lluka LJ, Wanstall JC: Specific uptake of 5-hydroxytryptamine is reduced in lungs from hypoxic pulmonary hypertensive rats. Eur J Pharmacol 396:137-140, 2000
64. Jollis JG, Landolfo CK, Kisslo J, Constantine GD, Davis KD, Ryan T: Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Circulation 101:2071-2077, 2000
65. Kanai Y, Hori S, Tanaka T, Yasuoka M, Watanabe K, Aikawa N, Hosoda Y: Role of 5- hydroxytryptamine in the progression of monocro- taline induced pulmonary hypertension in rats. Cardiovasc Res 27:1619-1623, 1993
66. Kaumann AJ, Levy FO: 5-Hydroxytryptamine receptors in the human cardiovascular system. Pharmacol Ther 111:674-706, 2006
67. Keane JF, Driscoll DJ, Gersony WM, Hayes CJ, Kidd L, O'Fallon WM, Pieroni DR, Wolfe RR, Weidman WH: Second natural history study of congenital heart defects. Results of treatment of patients with aortic valvar stenosis. Circulation 87:16-27, 1993
68. Keegan A, Morecroft I, Hicks MN, MacLean MR: Contribution of the 5-HT1B receptor to hypoxia- induced pulmonary hypertension. Converging evidence using 5-HTlB-receptor knockout mice and the 5-HT1B/1D antagonist GR127935. Circ Res 89:1231-1239, 2001
69. Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, Morgenstern LB, Wilterdink JL, Horwitz RI: Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 343:1826- 1832, 2000
70. Kopelman PG: Obesity as a medical problem. Nature 404:635-643, 2000
71. Korner J, Aronne LJ: Pharmacological approaches to weight reduction: therapeutic targets. J Clin Endocrinol Metab 89:2616-2621, 2004
72. Lambert DM, Fowler CJ: The endocannabinoid system: drug targets, lead compounds and potential therapeutic applications. J Med Chem 48:5059- 5087, 2005
73. Launay JM, Herve P, Peoc'h K, Tournois C, Callebert J, Nebigil CG, Etienne N, Drouet L, Humbert M, Simonneau G, Maroteaux L: Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 8:1129-1135, 2002
74. Lean ME: How does sibutramine work? Int J Obes Relat Metab Disord 25:S8-S11, 2001
75. Leung WY, Thomas GN, Chan JC, Tomlinson B: Weight management and current options in pharmacotherapy: orlistat and sibutramine. Clin Ther 25:58-80, 2003
76. Liu YL, Connoley IP, Wilson CA, Stock MJ: Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes 29:183-187, 2005
77. Long L, MacLean MR, Jeffery TK, Morecroft I, Yang X, Rudarakanchana N, Southwood M, James V, Trembath RC, Morrell NW: Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 98:818-827, 2006
78. Lucas KH, Kaplan-Machlis B: Orlistat-a novel weight loss therapy. Ann Pharmacothe 35:314-328, 2001
79. Machado RD, Aldred MA, James V, Harrison RE, Patel B, Schwalbe EC, Gruenig E, Janssen B, Koehler R, Seeger W, Eickelberg O, Olschewski H, Elliott CG, Glissmeyer E, Carlquist J, Kim M, Torbicki A, Fijalkowska A, Szewczyk G, Parma J, Abramowicz MJ, Galie N, Morisaki H, Kyotani S, Nakanishi N, Morisaki T, Humbert M, Simonneau G, Sitbon O, Soubrier F, Coulet F, Morrell NW, Trembath RC: Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 27:121-132, 2006
80. Mackie K: Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46:101-122, 2006
81. MacLean MR: Pulmonary hypertension, anorexi- gens and 5-HT-pharmacological synergism in action? Trends Pharmacol Sci 20:490-495, 1999
82. MacLean MR, Deuchar GA, Hicks MN, Morecroft I, Shen S, Sheward J, Colston J, Loughlin L, Nilsen M, Dempsie Y, Harmar A: Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation 109:2150- 2155, 2004
83. MacLean MR, Sweeney G, Baird M, McCulloch KM, Houslay M, Morecroft I: 5-Hydroxytrypta- mine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br J Pharmacol 119:917-930,1996
84. MacWalter RS, Fraser HW, Armstrong KM: Orlistat enhances warfarin effect. Ann Pharmac- other 37:510-512, 2003
85. Marcos E, Adnot S, Pham MH, Nosjean A, Raffestin B, Hamon M, Eddahibi S: Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 168:487-493, 2003
86. Martin F, Artigas F: Simultaneous effects of p- chloroamphetamine, d-fenfluramine, and reserpine on free and stored 5-hydroxytryptamine in brain and blood. J Neurochem 59:1138-1144, 1992
87. McDonald PC, Wilson JE, Gao M, McNeill S, Spinelli JJ, Williams OD, Harji S, Kenyon J, McManus BM: Quantitative analysis of human heart valves-does anorexigen exposure produce a distinctive morphological lesion? Cardiovasc Pathol 11:251-262, 2002
88. McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA: Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 22:814-822, 2002
89. McMurtry M, Moudgil R, Hashimoto K, Bonnet S, Michelakis E, Archer S: Overexpression of human bone morphogenetic protein receptor 2 does not ameliorate monocrotaline pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 292:L872-L878, 2007
90. Mekontso-Dessap A, Brouri F, Pascal O, Lechat P, Hanoun N, Lanfumey L, Seif I, Benhaiem-Sigaux N, Kirsch M, Hamon M, Adnot S, Eddahibi S: Deficiency in the 5-hydroxytryptamine transporter gene leads to cardiac fibrosis and valvulopathy in mice. Circulation 113:81-89, 2006
91. Melia AT, Koss-Twardy SG, Zhi J: The effect of orlistat, an inhibitor of dietary fat absorption on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 36:647-653, 1996
92. Michelakis ED, Weir EK: Anorectic drugs and pulmonary hypertension from the bedside to the bench. Am J Med Sci 321:292-299, 2001
93. Millan MJ, Maiofiss L, Cussac D, Audinot V, Boutin JA, Newman-Tancredi A: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmcol Exp Ther 303:791-804, 2002
94. Morales M, Wang SD, Diaz-Ruiz O, Jho DH: Cannabinoid CB1 receptor and serotonin 3 receptor subunit A (5-HT3A) are co-expressed in GABA neurons in the rat telencephalon. J Comp Neurol 468:205-216, 2004
95. National Institutes of Health, National Heart, Lung, and Blood Institute, in cooperation with the National Institute of Diabetes and Digestive and Kidney Diseases: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. NIH Publication No. 981083. US Government Press, Washington, DC, 1998
96. Nisoli E, Carruba MO: A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf 26:1027-1048, 2003
97. Osei-Hyiaman D, Depetrillo M, Harvey-White J, Bannon AW, Cravatt BF, Kuhar MJ, Mackie K, Palkovits M, Kunos G: Cocaine- and amphetamine-related transcript is involved in the orexi- genic effect of endogenous anandamide. Neuroen- docrinology 81:273-282, 2005
98. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, Harvey-White J, Mackie K, Offertaler L, Wang L, Kunos G: Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 115:1298-1305, 2005
99. Padwal R, Li SK, Lau DC: Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 27:1437- 1446, 2003
100. Padwal RS, Majumdar SR: Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369:71-77, 2007
101. Pagotto U, Vicennati V, Pasquali R: The endocannabinoid system and the treatment of obesity. Ann Med 37:270-275, 2005
102. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, Tuder RM: Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 43:25S-32S, 2004
103. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J: RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295:761- 775, 2006
104. Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE: Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77:1280-1286, 2002
105. Rajamannan NM, Caplice N, Anthikad F, Sebo TJ, Orszulak TA, Edwards WD, Tajik J, Schwartz RS: Cell proliferation in carcinoid valve disease: a mechanism for serotonin effects. J Heart Valve Dis 10:827-831, 2001
106. Reynolds AM, Xia W, Holmes MD, Hodge SJ, Danilov S, Curiel DT, Morrell NW, Reynolds PN: Bone morphogenetic protein type 2 receptor gene therapy attenuates hypoxic pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 292:L1182-L1192, 2007
107. Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L: Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 117:870-874, 2000
108. Rich S, Shillington A, McLaughlin V: Comparison of survival in patients with pulmonary hypertension associated with fenfluramine to patients with primary pulmonary hypertension. Am J Cardiol 92:1366-1368, 2003
109. Rinaldi-Carmona M, Barth F, Congy C, Martinez S, Oustric D, Perio A, Poncelet M, Maruani J, Arnone M, Finance O, Soubrie P, Le Fur G: SR147778 [5-(4-bromophenyl)-l-(2,4-dichlorophe- nyl)-4-ethyl-N-(l-piperidinyl)-lH- pyrazole-3-carbox- amide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization. J Pharmacol Exp Ther 310:905-914, 2004
110. Roth BL: Drugs and valvular heart disease. N Engl J Med 356:6-9, 2007
111. Rothman RB, Michael H, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL: Evidence for possible involvement of 5HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 101:2836-2841, 2000
112. Rubin LJ: Primary pulmonary hypertension. N Engl J Med 336:111-117, 1997
113. Sachdev M, Miller WC, Ryan T, Jollis JG: Effect of fenfluramine- derivative diet pills on cardiac valves: a meta-analysis of observational studies. Am Heart J 144:1065-1073, 2002
114. Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E: Dopamine agonists and the risk of cardiac- valve regurgitation. N Engl J Med 356:29-38, 2007
115. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, RIO-Diabetes Study Group, Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes. Lancet 368:1160 - 1172, 2006
116. Setola V, Hufeisen SJ, GrandeAllen KJ, Vesely I, Glennon RA, Blough B, Rothman RB, Roth BL: 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy") induces fenfluramine-like proliferative actions of human cardiac valvular interstitial cells in vitro. Mol Pharmacol 63:1223-1229, 2003
117. Setola V, Roth BL: Screening the receptorme reveals molecular targets responsible for drug- induced side effects: focus on 'fen-phen.' Expert Opin Drug Metab Toxicol 1:377-387, 2005
118. Shillingford CA, Vose CW: Effective decision making: progressing compounds through clinical development. Drug Discov Today 6:941-946, 2001
119. Simonneau G, Fartoukh M, Sitbon O, Humbert M, Jagot JL, Herve P: Primary pulmonary hypertension associated with the use of fenfluramine derivatives. Chest 114:195S-199S, 1998
120. SoRelle R: Diet drug maker agrees to $3.75 billion settlement. Circulation 100:133-134, 1999
121. Souza R, Humbert M, Sztrymf B, Jais X, Yaici A, Le Pavec J, Parent F, Herve P, Soubrier F, Sitbon O, Simonneau G: Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases. Eur Respir J 31:343-348, 2008
122. Staten MA: Challenges in the discovery and development of new agents for the treatment of obesity. Clin Pharmacol Ther 81:753-755, 2007
123. Stubbs EG, Budden SS, Jackson RH, Terdal LG, Ritvo ER: Effects of fenfluramine on eight outpatients with the syndrome of autism. Dev Med Child Neurol 28:229-235, 1986
124. Thorn T, Haase N, Rosamond W, Howard VJ, Rumsfeld J, Manolio T, Zheng ZJ, Flegal K, O'Donnell C, Kittner S, Lloyd-Jones D, Goff DC Jr, Hong Y, Adams R, Friday G, Furie K, Gorelick P, Kissela B, Marler J, Meigs J, Roger V, Sidney S, Sorlie P, Steinberger J, Wasserthiel-Smoller S, Wilson M, Wolf P: American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113:e85-el51, 2006
125. Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zuniga-Guajardo S, Van Gaal L: X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance. Diabetes Obes Metab 7:699-708, 2005
126. Traynor K: Panel advises against Rimonabant approval. Am J Health Syst Pharm 64:1460-1461, 2007
127. US Department of Health and Human Services, Public Health Service: The Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity, Office of the Surgeon General, Rockville, MD, 2001
128. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S and for the RIO-Europe Study Group: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365:1389-1397, 2005
129. Volmar KE, Hutchins GM: Aortic and mitral fenfluramine-phentermine valvulopathy in 64 patients treated with anorectic agents. Arch Pathol Lab Med 125:1555-1561, 2001
130. Wang Y, Beydoun MA: The obesity epidemic in the United States-gender, age, socioeconomic, racial/ ethnic, and geographic characteristics: a systematic review and meta-regression analysis. Epidemiol Rev 29:6-28, 2007
131. Weibel EK, Hadvary P, Hochuli E, Kupfer E, Lengsfeld H: Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini, I: producing organism, fermentation, isolation and biological activity. J Antibiot 40:1081-1085, 1987
132. Wolfe BM, Morton JM: Weighing in on bariatric surgery: procedure use, readmission rates, and mortality. JAMA 294:1960-1963, 2005
133. Wooltorton E: Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias. CMAJ 166:1307-1308, 2002
134. Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G: Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356:3916, 2007
135. Zheng Y, Russell B, Schmierer D, Laverty R: The effects of aminorex and related compounds on brain monoamines and metabolites in CBA mice. J Pharm Pharmacol 49:89-96, 1997
136. Zhi J, Moore R, Kanitra L: The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and micro- minerals in obese adolescents. J Am Coll Nutr 22:357-362, 2003
137. Zhi J, Moore R, Kanitra L, Mulligan TE: Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in health subjects. J Clin Pharmacol 42:1011-1019, 2002